Payment overview · 2025
General Payments
$1,014.92
49 reported records · 17 companies
Healthcare provider profile · identity verified
Daniel Sewell, MD
Allopathic & Osteopathic Physicians|Family Medicine · AUBURN, CA · NPI 1609979723
Verified facts
What the public records show
CMS Open Payments records show Daniel Sewell, MD received $1,014.92 in general payments during 2025 across 49 reported records.
Corcept Therapeutics accounted for 15.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $151.83 | 15.0% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $145.62 | 14.3% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.09 | 14.3% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $126.95 | 12.5% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $96.18 | 9.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.19 | 5.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.75 | 5.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.74 | 4.2% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $33.66 | 3.3% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.56 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.87 | 2.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.08 | 2.3% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.11 | 1.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.06 | 1.5% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $14.83 | 1.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.72 | 1.4% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $7.68 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,014.92 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $151.83 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $126.95 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.48 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $111.48 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $96.18 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $81.41 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $81.41 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $72.66 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $59.19 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $59.19 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $58.75 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $54.01 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.14 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $33.66 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $33.56 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $28.87 | 1 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 126 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 597 | 206 |
| Levothyroxine Sodium | Levothyroxine Sodium | 399 | 144 |
| Losartan Potassium | Losartan Potassium | 376 | 144 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 365 | 83 |
| Lisinopril | Lisinopril | 325 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 278 | 88 |
| Gabapentin | Gabapentin | 238 | 89 |
| Omeprazole | Omeprazole | 236 | 82 |
| Metformin Hcl | Metformin Hcl | 228 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 59 |
| Simvastatin | Simvastatin | 149 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 146 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 36 |
| Trazodone Hcl | Trazodone Hcl | 134 | 50 |
| Eliquis | Apixaban | 126 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 57 |
| Ozempic | Semaglutide | 119 | 25 |
| Jardiance | Empagliflozin | 110 | 33 |
| Allopurinol | Allopurinol | 105 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 31 |
| Meloxicam | Meloxicam | 90 | 26 |
| Atenolol | Atenolol | 88 | 28 |
| Furosemide | Furosemide | 88 | 42 |
| Alprazolam | Alprazolam | 85 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 26 |
| Potassium Chloride | Potassium Chloride | 84 | 33 |
| Ibuprofen | Ibuprofen | 75 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 19 |
| Montelukast Sodium | Montelukast Sodium | 73 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 26 |
| Donepezil Hcl | Donepezil Hcl | 70 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 25 |
| Carvedilol | Carvedilol | 67 | 24 |
| Valacyclovir | Valacyclovir Hcl | 65 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | 11 |
| Lovastatin | Lovastatin | 61 | 16 |
| Baclofen | Baclofen | 60 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 24 |
| Alendronate Sodium | Alendronate Sodium | 58 | 18 |
| Diazepam | Diazepam | 57 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 17 |
| Metformin Hcl Er | Metformin Hcl | 56 | 16 |
| Tramadol Hcl | Tramadol Hcl | 55 | 21 |
| Lorazepam | Lorazepam | 54 | 13 |
| Mirtazapine | Mirtazapine | 52 | 11 |
| Prednisone | Prednisone | 51 | 33 |
| Finasteride | Finasteride | 49 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 15 |
| Azelastine Hcl | Azelastine Hcl | 47 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 20 |
| Azithromycin | Azithromycin | 45 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 13 |
| Bupropion Xl | Bupropion Hcl | 42 | 16 |
| Ezetimibe | Ezetimibe | 42 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 42 | suppressed |
| Estradiol | Estradiol | 40 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 15 |
| Xarelto | Rivaroxaban | 38 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Glimepiride | Glimepiride | 36 | 14 |
| Sertraline Hcl | Sertraline Hcl | 36 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 35 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 12 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | 12 |
| Celecoxib | Celecoxib | 31 | 13 |
| Farxiga | Dapagliflozin Propanediol | 31 | 11 |
| Spironolactone | Spironolactone | 31 | 14 |
| Synthroid | Levothyroxine Sodium | 31 | 11 |
| Famotidine | Famotidine | 30 | 13 |
| Acyclovir | Acyclovir | 28 | 14 |
| Clonidine Hcl | Clonidine Hcl | 28 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 26 |
| Rybelsus | Semaglutide | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | 12 |
| Buprenorphine | Buprenorphine | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 15 |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 18 |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Armour Thyroid | Thyroid,pork | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Xtampza Er | Oxycodone Myristate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 13 |
| Hysingla Er | Hydrocodone Bitartrate | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,014.92 · 49 records | Corcept Therapeutics | BREZTRI, CREON, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, ID NOW INSTRUMENT, KISUNLA, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PYRUKYND, REZDIFFRA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, Wegovy, XTAMPZA, ZAVZPRET, ZEPBOUND, ZTLido | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error